Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

Many pathogens use the same immune evasion mechanisms as cancer cells. Patients with chronic infections have elevated levels of checkpoint receptors (e.g., programed cell death 1, PD1) on T cells. Monoclonal antibody (mAb)-based inhibitors to checkpoint receptors have also been shown to enhance T-ce...

Full description

Bibliographic Details
Main Authors: Vinayaka Kotraiah, Timothy W. Phares, Cecille D. Browne, James Pannucci, Marc Mansour, Amy R. Noe, Kenneth D. Tucker, Jayne M. Christen, Charles Reed, Alecia MacKay, Genevieve M. Weir, Rajkannan Rajagopalan, Marianne M. Stanford, Chun-Shiang Chung, Alfred Ayala, Jing Huang, Moriya Tsuji, Gabriel M. Gutierrez
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Immunology
Subjects:
vaccine
peptides
adjuvant
checkpoint
T-cell
cancer
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00264/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00264/full

Similar Items